Agendia Announces Intention to List on NYSE Euronext in Amsterdam

Amsterdam (ots/PRNewswire) - Agendia (the "Company"), a
commercial-stage molecular diagnostic company with operations in the
Netherlands and the United States, announces today its intention to
raise new funds through an initial public offering ("IPO") on NYSE
Euronext in Amsterdam.

Agendia is focused on the discovery, development and
commercialisation of molecular diagnostic products that help
physicians to make personalised treatment decisions for their cancer
patients. The Company is currently marketing its Symphony(TM) suite
of four complementary breast cancer tests, which provides a
comprehensive support system for oncologists to determine whether a
patient is likely to benefit from hormonal therapy, chemotherapy or
targeted therapies. Agendia is also developing a pipeline of
genomic-based diagnostic products, including a further extension of
its breast cancer suite of tests as well as products for colon cancer
and lung cancer.

Agendia intends to use the net proceeds of the IPO primarily to
expand sales and marketing activities in its breast cancer franchise,
particularly in the United States, and to complete technical
validation and initiate commercialisation of its ColoPrint(R) colon
cancer test.

Details on the offering will be announced in due course, subject
to approval of the prospectus by the Netherlands Authority for
Financial Markets and market conditions.

ABN AMRO and ING have been appointed as joint global coordinators
and joint bookrunners for the IPO. KBC Securities and Kempen & Co are
acting as co-lead managers.

About Agendia

Agendia is a commercial-stage molecular diagnostic company
focused on the discovery, development and commercialisation of
genomic-based diagnostic products to improve the quality of life for
cancer patients by providing healthcare professionals with critical
information to enable safe and effective personalised treatment. The
Company's Symphony(TM) suite of four complementary breast cancer
tests, TargetPrint(R), MammaPrint(R), BluePrint(TM) and
TheraPrint(R), provides a comprehensive support system for
oncologists to determine whether a breast cancer patient is likely to
benefit from hormonal therapy, chemotherapy or targeted therapies,
saving patients from unnecessary treatments and lowering healthcare
costs. Agendia's lead test, MammaPrint(R), currently the only
molecular diagnostic breast cancer recurrence test to receive
clearance from the US Food and Drug Administration, gives physicians
a tool to clearly and decidedly separate "high" risk from "low" risk
recurrence in early stage breast cancer patients, thereby better
gauging the "high" risk patients' need for chemotherapy. Agendia is
advancing a pipeline of new products, which includes a further
extension of its breast cancer suite of tests as well as products for
colon cancer and lung cancer. The Company's research and development
activities are driven by its deep scientific roots and supported by
collaborations with leading academic consortia, cancer centres and
pharmaceutical companies.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Amsterdam, the Netherlands, and
Irvine, California, United States. For more information, please visit
http://www.agendia.com .

Disclaimer

This announcement and the information contained herein are not
for distribution in or into the United States of America (including
its territories and possessions, any state of the United States of
America and the District of Columbia) (the "United States"),
Australia, Canada or Japan. This announcement does not constitute, or
form part of, an offer to sell or a solicitation of any offer to
purchase the shares of Agendia (the "Company", and such shares, the
"Securities") in the United States, Australia, Canada, Japan or in
any other jurisdiction where such offer or sale could be unlawful.

The Securities have not been and will not be registered under the
US Securities Act of 1933, as amended (the "Securities Act"), or with
any securities regulatory authority of any state or other
jurisdiction of the United States. Consequently, the Securities may
not be offered, sold, resold, transferred, delivered or distributed,
directly or indirectly, into or within the United States except
pursuant to an exemption from the registration requirements of the
Securities Act and in compliance with any applicable securities laws
of any state or other jurisdiction of the United States. No public
offering of the Securities is being made in the United States.

This communication is only addressed to, and directed at, persons
in member states of the European Economic Area who are "qualified
investors" within the meaning of Article 2(1)(e) of the Prospectus
Directive ("Qualified Investors"). For the purposes of this
provision, the expression "Prospectus Directive" means Directive
2003/71/EC (and amendments thereto, including Directive 2010/73/EC,
to the extent implemented in the Relevant Member State) and includes
any relevant implementing measure in each member state of the
European Economic Area which has implemented the Prospectus
Directive. This document is an advertisement and not a prospectus for
the purpose of the Prospectus Directive. A prospectus prepared
pursuant to the Prospectus Directive is intended to be published,
which, when published, can be obtained from Agendia. Investors should
not subscribe for any securities referred to in this document except
on the basis of information contained in the prospectus.

In addition, in the United Kingdom, this communication is being
distributed only to, and is directed only at, Qualified Investors (i)
who have professional experience in matters relating to investments
who fall within the definition of "investment professional" in
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order"), or (ii)
who are high net worth companies, unincorporated associations and
partnerships and trustees of high value trusts as described in
Article 49(2) of the Order, and (iii) other persons to whom it may
otherwise lawfully be communicated (all such persons together being
referred to as "relevant persons"). Any investment or investment
activity to which this communication relates is available only to and
will only be engaged in with such persons. This communication must
not be acted on or relied on (i) in the United Kingdom, by persons
who are not relevant persons and (ii) in any member state of the
European Economic Area other than the United Kingdom, by persons who
are not Qualified Investors.

In connection with the Offering, one of the Underwriters (the
"Stabilising Manager") (or persons acting on behalf of the
Stabilising Manager) may over-allot shares or effect transactions
with a view to supporting the market price of the shares at a level
higher than that which might otherwise prevail. However, there is no
assurance that the Stabilising Manager (or persons acting on behalf
of the Stabilising Manager) will undertake stabilisation action. Any
stabilisation action may begin on or after the date on which adequate
public disclosure of the final price of the shares is made and, if
begun, may be ended at any time, but it must end no later than 30
days after the date of commencement of trading of the shares.

The information, opinions and forward-looking statements
contained in this release speak only as at its date, and are subject
to change without notice.

All investment is subject to risk. The price of the securities
offered may fluctuate. Past performance is no guarantee of future
returns. Potential investors are advised to seek expert financial
advice before making any investment decision.

Aan de belegging zijn risico's verbonden. De waarde van de
aangeboden effecten kan fluctueren. Rendementen uit het verleden zijn
geen garantie voor de toekomst. Potentiële beleggers wordt
geadviseerd om eerst hun eigen beleggingsadviseur te raadplegen
alvorens een beleggingsbesluit te nemen.

For further information, please contact:
Agendia
Dr. Bernhard Sixt, President & CEO
Investorrelations@agendia.com
International media and investor enquiries
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel: +44(0)20-7920-2345, E-mail: Agendia@mcomgroup.com
Dutch media enquiries
Huijskens Communications
Ian Bickerton
Tel +31(0)20-685-5955
Email: i.bickerton@huijskens.nl

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.